Spoken Alpha
LakeShore Biopharma Co., Ltd.
LakeShore Biopharma Co., Ltd is a Healthcare company operating in Biotechnology with a $2.9M market cap.
Most recent earnings call: Q3 FY24 on Apr 19, 2024.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks LSBCF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 70% of the time
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LSBCF.
$ curl https://api.spokenalpha.com/v1/companies/LSBCFFAQ
Spoken Alpha indexes LSBCF's earnings call transcripts at https://spokenalpha.com/companies/LSBCF. Each call links to attributed speakers and parsed analyst Q&A.
LakeShore Biopharma Co., Ltd. (LSBCF) held its most recent earnings call on 2024-04-19, covering fiscal Q3 2024.
LakeShore Biopharma Co., Ltd. (LSBCF) operates in the Healthcare sector (Biotechnology industry).
When a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2024 | $2.10 | $1.75 | +20.1% | -5.2% | -5.6% |
| Q4 FY2024 | $2.08 | $1.59 | +31.0% | -2.1% | +0.5% |
| Q3 FY2024 | $2.22 | $1.70 | +30.4% | -2.4% | -2.0% |
| Q2 FY2024 | $2.12 | $1.66 | +27.5% | -7.1% | -6.2% |
| Q1 FY2023 | $2.21 | $1.75 | +26.1% | -1.3% | -3.6% |
| Q4 FY2023 |
| $2.09 |
| $1.75 |
| +19.3% |
| +0.8% |
| +0.7% |
| Q3 FY2023 | $2.24 | $1.82 | +23.3% | +2.0% | +1.8% |
| Q2 FY2023 | $2.40 | $1.93 | +24.3% | -1.3% | -0.9% |
| Q1 FY2022 | $2.16 | $1.80 | +20.0% | -7.6% | -4.7% |
| Q4 FY2022 | $2.28 | $1.73 | +32.0% | +1.8% | +2.2% |